Authors
Yuankai Hao, Zelu Zhang, Shicheng Wang, Ke Wang, Xiaohui Liu, Ping Liu
Published in
Molecular therapy : the journal of the American Society of Gene Therapy. Sep 30, 2026. Epub Sep 30, 2026.
Abstract
Although immune checkpoint blockade (ICB) represented by anti-PD-1 therapy has demonstrated significant clinical benefits, its efficacy remains limited by the immunosuppressive tumor microenvironment (TME). Our study revealed that the combination of Cryo-thermal therapy (CTT) and anti-PD-1 therapy suppresses the distal tumor growth compared to either cryoablation or radiofrequency ablation combined with anti-PD-1 therapy. Mechanistically, CTT specifically induces TNF-α production in mature myeloid cells, triggering autocrine CCL5 secretion that recruits peripheral IFN-γ+ T cells induced by CTT in distal tumors, creating a cytokine loop in which IFN-γ derived from T cells and TNF-α derived from myeloid cells collectively promote CCL5 secretion in myeloid cells to increase effector T-cell recruitment in distal tumors. After CTT, anti-PD-1 treatment amplifies this cascade by enhancing TNF-α production in T cells. The parallel activation of STAT1 by IFN-γ and NF-κB by TNF-α in myeloid cells converges to drive IRF7-dependent CCL5 upregulation to create a local immune enhancing environment via CCL5-mediated recruitment of T cells. Our study demonstrates that CTT establishes an immunologically favorable TME by reprogramming immunosuppressive myeloid cells into mature myeloid cells with high CCL5 production, thereby facilitating effector T-cell recruitment, providing an efficient therapeutic strategy to promote the response to anti-PD-1 therapy.
PMID:
42817167
Bibliographic data and abstract were imported from PubMed on 01 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 21
- Comments 0